Antimicrobial susceptibility of Gram-negative bacteria causing intra-abdominal infections in China: SMART China 2011

Chinese Medical Journal

Volumn 127, Issue 13, 2014, Pages 2429-2433

  Zhang, Hui ^a   Yang, Qi Wen ^a   Xiao, Meng ^a   Chen, Min Jun ^a   Badal, Robert E ^b   Xu, Ying Chun ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b Division of Microbiology   (United States)

Author keywords

Enterobacteriaceae; Extended spectrum lactamase; Intra abdominal infections; Study for Monitoring Antimicrobial Resistance Trends (SMART)

Indexed keywords

ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; CHINA; CLASSIFICATION; DRUG EFFECTS; ENTEROBACTERIACEAE; GENETICS; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOGENICITY;

ANTI-BACTERIAL AGENTS; CHINA; ENTEROBACTERIACEAE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INTRAABDOMINAL INFECTIONS; MICROBIAL SENSITIVITY TESTS;

EID: 84904265932     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20131538     Document Type: Article

References (21)

1. Doshi RK, Patel G, Mackay R, Wallach F. Healthcare-associated infections: epidemiology, prevention, and therapy. Mt Sinai J Med 2009; 76: 84-94.
2. Kuo KC, Shen YH, Hwang KP. Clinical implications and risk factors of extended-spectrum beta-lactamase-producing Klebsiella pneumonia infection in children: a case-control retrospective study in a medical center in southern Taiwan. J Microbiol Immunol Infect 2007; 40: 248-254.
3. Lockhart SR, Abramson MA, Beekmann SE, Gallagher G, Riedel S, Diekema DJ, et al. Antimicrobial resistance among gram-negative bacilli causing infections in intensive care units in the United States between 1993 and 2004. J Clin Microbiol 2007; 45: 3352-3359.
4. Su MS, Lin MH, Zhao QH, Liu ZW, He L, Jia N. Clinical study of distribution and drug resistance of pathogens in patients with severe acute pancreatitis. Chin Med J 2012; 125: 1772-1776.
5. Paterson DL, Rossi F, Baquero F, Hsueh PR, Woods GL, Satishchandran V, et al. In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: The 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 2005; 55: 965-973.
6. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically-Eighth Edition: approved standard M7-A8. CLSI; 2009; Wayne, PA, USA.
7. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twenty-second informational supplement. Document M100-S22. CLSI; 2012; Wayne, PA, USA.
8. Blot S, De Waele JJ, Vogelaers D. Essentials for selecting antimicrobial therapy for intra-abdominal infections. Drugs 2012; 72: e17-e32.
9. Montravers P, Lepape A, Dubreuil L, Gauzit R, Pean Y, Benchimol D, et al. Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study. J Antimicrob Chemother 2009; 63: 785-794.
10. Fraser A, Paul M, Almanasreh N, Tacconelli E, Frank U, Cauda R, et al. Benefit of appropriate empirical antibiotic treatment: Thirty-day mortality and duration of hospital stay. Am J Med 2006; 119: 970-976.
11. Shrestha S, Amatya R, Dutta R. Prevalence of extended spectrum beta lactamase (ESBL) production in gram negative isolates from pyogenic infection in tertiary care hospital of eastern Nepal. Nepal Med Coll J 2011; 13: 186-189.
12. Toh HS, Chuang YC, Huang CC, Lee YL, Liu YM, Ho CM, et al. Antimicrobial susceptibility profiles of Gram-negative bacilli isolated from patients with hepatobiliary infections in Taiwan: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2006-2010. Int J Antimicrob Agent 2012; 40S1: S18-S23.
13. Tinelli M, Cataldo MA, Mantengoli E, Cadeddu C, Cunietti E, Luzzaro F, et al. Epidemiology and genetic characteristics of extended-spectrum β-lactamase-producing Gram-negative bacteria causing urinary tract infections in long-term care facilities. J Antimicrob Chemother 2012; 67: 2982-2987.
14. Cantón R, Loza E, Aznar J, Calvo J, Cercenado E, Cisterna R, et al. Antimicrobial susceptibility of Gram-negative organisms from intra-abdominal infections and evolution of isolates with extended spectrum β-lactamases in the SMART study in Spain (2002-2010). Rev Esp Quimioter 2011; 24: 223-232.
15. Chanawong A, M'Zali FH, Heritage J, Xiong JH, Hawkey PM. Three cefotaximases, CTX-M-9 CTX-M-13, and CTX-M-14, among Enterobacteriaceae in the People's Republic of China. Antimicrob Agents Chemother 2002; 46: 630-637.
16. Wang H, Kelkar S, Wu W, Chen M, Quinn JP. Clinical isolates of Enterobacteriaceae producing extended-spectrum beta-lactamases: prevalence of CTX-M-3 at a hospital in China. Antimicrob Agents Chemother 2003; 47: 790-793.
17. Wang H, Dzink-Fox JL, Chen M, Levy SB. Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: role of acrR mutations. Antimicrob Agents Chemother 2001; 45: 1515-1521.
18. Ben-Ami R, Arslan H, Pitout JD, Quentin C, Calbo ES, Azap OK, et al. A multinational survey of risk factors for infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009; 49: 682-690.
19. Livermore DM, Oakton KJ, Carter MW, Warner M. Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent β-lactamases. Antimicrob Agents Chemother 2001; 45: 2831-2837.
20. Essack SY. Treatment options for extended-spectrum β-lactamase-producers. FEMS Microbiol Lett 2000; 190: 181-184.
21. Paterson DL. Recommendations for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs). Clin Microbiol Infect 2000; 6: 460-463.